scholarly journals Determinants of Primary Nonadherence to Medications Prescribed by General Practitioners Among Adults in Hungary: Cross-Sectional Evaluation of Health Insurance Data

2019 ◽  
Vol 10 ◽  
Author(s):  
Nouh Harsha ◽  
László Kőrösi ◽  
Anita Pálinkás ◽  
Klára Bíró ◽  
Klára Boruzs ◽  
...  
Keyword(s):  
Health Insurance ◽  
General Practitioners ◽  
Health Insurance Data ◽  
Cross Sectional ◽  
Primary Nonadherence ◽  
Insurance Data

scholarly journals Using statutory health insurance data to evaluate non-response in a cross-sectional study on depression among patients with diabetes in Germany

2020 ◽  
Vol 49 (2) ◽  
pp. 629-637 ◽  
Author(s):  
Ute Linnenkamp ◽  
Veronika Gontscharuk ◽  
Manuela Brüne ◽  
Nadezda Chernyak ◽  
Tatjana Kvitkina ◽  
...  
Keyword(s):  
Health Insurance ◽  
Cross Sectional Study ◽  
Response Analysis ◽  
Cross Sectional Survey ◽  
Health Insurance Data ◽  
Cross Sectional ◽  
Depression Diagnosis ◽  
Medication Utilization ◽  
Patients With Diabetes ◽  
Insurance Data

Abstract Background Low response rates do not indicate poor representativeness of study populations if non-response occurs completely at random. A non-response analysis can help to investigate whether non-response is a potential source for bias within a study. Methods A cross-sectional survey among a random sample of a health insurance population with diabetes (n = 3642, 58.9% male, mean age 65.7 years), assessing depression in diabetes, was conducted in 2013 in Germany. Health insurance data were available for responders and non-responders to assess non-response bias. The response rate was 51.1%. Odds ratios (ORs) for responses to the survey were calculated using logistic regression taking into consideration the depression diagnosis as well as age, sex, antihyperglycaemic medication, medication utilization, hospital admission and other comorbidities (from health insurance data). Results Responders and non-responders did not differ in the depression diagnosis [OR 0.99, confidence interval (CI) 0.82–1.2]. Regardless of age and sex, treatment with insulin only (OR 1.73, CI 1.36–2.21), treatment with oral antihyperglycaemic drugs (OAD) only (OR 1.77, CI 1.49–2.09), treatment with both insulin and OAD (OR 1.91, CI 1.51–2.43) and higher general medication utilization (1.29, 1.10–1.51) were associated with responding to the survey. Conclusion We found differences in age, sex, diabetes treatment and medication utilization between responders and non-responders, which might bias the results. However, responders and non-responders did not differ in their depression status, which is the focus of the DiaDec study. Our analysis may serve as an example for conducting non-response analyses using health insurance data.

P–742 Medical contraceptive use in the French population: Can we explore it based on the national health insurance data?

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
J Congy ◽  
J Bouyer ◽  
D Rahib ◽  
E D L Rochebrochard
Keyword(s):  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Contraceptive Use ◽  
Population Based ◽  
Health Insurance Data ◽  
Cross Sectional ◽  
Insurance Data ◽  
Copper Iud ◽  
Population Based Survey

Abstract Study question Are French national health insurance data reliable for studying the use of medical contraception? Summary answer Health insurance data produce a measurement of contraceptive use consistent with population-based survey data, which affords new opportunities for studying contraception. What is known already Medical contraception is a major public health issue as most women of reproductive age use it. It is usually studied through population-based surveys. However, such surveys are conducted only every 10 years, and analyses are limited by their sample size. French national health insurance data provide comprehensive and time-continuous information on each reimbursed contraceptive. However, because these data have been collected for a different purpose (reimbursement), their relevance for measuring the use of contraceptives needs to be assessed. Study design, size, duration Two sources were analysed. First, a cross-sectional cohort was extracted from the health insurance database, which includes all health reimbursements (such as those for medical contraceptives) and covers 98% of the French population, including 14 million women aged 15–49. Secondly, we used the last French survey on contraception, a cross-sectional study including 4,508 women aged 15–49 interviewed by phone. Participants/materials, setting, methods From both sources, we selected all women aged 15–49 living in metropolitan France. We identified the last medical contraceptive purchased by each woman between 2014 and 2019. The woman was then classified as currently using this contraceptive if the recommended duration of use for this contraceptive was still ongoing on 31 December 2019. Prevalences were compared to those observed in the population based survey. Main results and the role of chance Among the 14.3 million women aged 15–49 living in metropolitan France covered by the health insurance, 26.0% were using the pill, 17.4% an IUD (7.6% hormonal IUD; 9.9% copper IUD), and 3.1% an etonogestrel implant. These proportions are very close to and not statistically different from those observed in the population-based survey (26.2% for the pill, 18.4% IUD, and 3.1% implant). Contraceptive use varied widely with women’s age. At ages 20–24, the most widely used contraceptive was the pill (42.2%), and very few long-acting contraceptives were used (7.6% IUD; 4.9% implant). At ages 30–34, the pill was less frequently used (21.6%) and IUD more frequently used (copper IUD: 15.79%; hormonal IUD: 7.06%). Limitations, reasons for caution It cannot be ruled out that some contraceptives were purchased but never used and that a few women stopped using the contraceptive before the end of its recommended duration. Wider implications of the findings: To our knowledge, this study is the first to estimate prevalence for Copper IUD and for hormonal IUD in France. Using the national health insurance database, it is now possible to monitor the use of each type of medical contraceptive over time in a reliable population-based approach. Trial registration number Not applicable

A study on the health effects of residents in Namhae and Hadong - Centered on health insurance data

2020 ◽  
Vol 19 (3) ◽  
pp. 268-277
Author(s):  
YoonDeok Han ◽  
◽  
Sunghyeon Jung ◽  
Kwang-tae Ha ◽  
Seung-Mi Kwon ◽  
...  
Keyword(s):  
Health Insurance ◽  
Health Effects ◽  
Health Insurance Data ◽  
Insurance Data

A Novel Approach for Labelling Health Insurance Data for Cardiovascular Disease Risk Classification

2016 ◽  
Author(s):  
César L. C. Mattos ◽  
Amauri H. Souza Júnior ◽  
Ajalmar R. Rocha Neto ◽  
Guilherme A. Barreto ◽  
Ronaldo F. Ramos ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Health Insurance ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Risk Classification ◽  
Health Insurance Data ◽  
Novel Approach ◽  
Insurance Data
Sign in / Sign up

Export Citation Format

Share Document